Introduction
TRIM (tripartite motif) proteins form a family of dozens of members, most of them showing a RING, a B-box and a Coiled-coil domains.
1,2 TRIM5a was isolated in 2004 as the factor governing the resistance of rhesus macaque monkeys to transduction by human immunodeficiency virus (HIV)-1 vectors. 3 Shortly thereafter, most primates were shown to encode TRIM5a orthologues each having the capacity to restrict a particular range of retroviruses. [4] [5] [6] [7] [8] [9] As would be expected, TRIM5a from a particular species does not inhibit cognate retroviruses, but it can target retroviruses from other species, thereby contributing to the prevention of inter-species transmission. Human TRIM5a inhibits some retroviruses, such as the equine infectious anemia virus (EIAV) and the so-called 'N strains' of the murine leukemia virus (N-MLV) 4 ,5,10,11 but it only weakly restricts HIV-1, HIV-2 and many simian immunodeficiency viruses (SIVs), including SIVs from macaques (SIV mac ), from African green monkeys (SIV AGM ) and from chimpanzees (SIV cpz ). 5, 12, 13 It is likely that the limited restriction range of TRIM5a hu has made it possible for lentiviruses infecting nonhuman primates to cross-species and thrive in humans, thus causing the current HIV pandemic. It has been suggested that TRIM5a hu derives from an ancestor gene that had evolved to provide resistance against unknown, now-extinct retroviruses, leaving us more vulnerable to infections by modern simian lentiviruses. 14 Restriction by TRIM5a is initiated by physical recognition of incoming retroviruses by TRIM5a proteins. 15, 16 This interaction occurs within the first hours after virus entry. 17 and involves determinants present in the N-terminal domain of the capsid proteins that constitute the retroviral outer core structure. [18] [19] [20] After this initial contact, progression of the retroviral life cycle is impeded through several mechanisms. Viral cores seem to undergo accelerated uncoating, as evidenced by the disappearance of capsid in particulate form. 16, 21, 22 The proteasome is also involved and causes a decrease in retroviral complementary DNA accumulation in acutely infected cells. 23 TRIM5a proteins can seemingly selfubiquitinate 24, 25 and are rapidly degraded by the proteasome on exposure to a restriction-sensitive virus. 26 Finally, TRIM5a interferes with the transport of postentry retroviral complexes toward the nucleus, and this antiviral activity is independent from the one involving the proteasome. 27, 28 As retroviral replication is blocked in the cytoplasm and within the first hours of infection, successful restriction by TRIM5a is expected to completely prevent de novo transcription of viral genes from integrated or unintegrated viral complementary DNAs in the nucleus.
In addition to the RING, a B-box and a Coiled-coil motif, TRIM5a contains a C-terminal PRYSPRY domain (also called SPRY or B30. 2) 29 that is the sole determinant of restriction specificity. 30 PRYSPRY is the most variable domain of TRIM5a, and it contains four highly variable regions (see Figure 1d ), labeled v1-v4, 31 although only v1-v3 are generally considered relevant to restriction specificity. Construction of chimeric genes in which these three variable regions are swapped between TRIM5a orthologues showed that all three of them can potentially contribute to restriction specificity. 32 Particular attention has been given to the v1 region, which is rich in positively (that is, non-randomly) selected aminoacids. 33, 34 Versions of human TRIM5a in which short stretches of the v1 region were replaced by those of the macaque orthologue showed restriction activity against HIV-1. 33, 35 In particular, substitution of TRIM5a hu arginine 332 for a proline (the aminoacid present at that position in TRIM5a rh ) decreased permissiveness to HIV-1 infection. [35] [36] [37] In fact, most substitutions of this residue, excepted to a lysine, resulted in significant HIV-1 restriction, showing that suppression of the positive charge was the mechanism underlying the acquisition of HIV-1 restriction potential. 36 Although the protection provided by mutations at position 332 was strong (10-to 30-fold), these mutants still restricted HIV-1 10-times less efficiently than TRIM5a rh did. 36 Numerous gene therapy clinical trials for the treatment of AIDS have been undertaken to mostly disappointing results, both in terms of viral load and of CD4+ T cells counts. 38 In particular, although it is desirable that transgene-expressing cells survive and proliferate in the recipient patients, the opposite is often observed. For instance, after gene transfer of an anti-HIV ribozyme in hematopoietic stem cells, a fivefold reduction in expression of the ribozyme was observed within 6 months. 39 Rapid elimination of productively HIV-1-infected lymphocytes is well-known 40 and results from the action of cytotoxic T lymphocytes and also from virus-related killing. Therefore, it is likely that to succeed, a gene therapy approach for AIDS would need to disrupt viral replication either at entry or at immediate post-entry steps, before viral antigens are being synthesized. Interfering with the expression of the virus entry coreceptor CCR5, either by RNA interference 41, 42 or by transfer of a zinc-finger nuclease 43 might achieve that goal, but the immunological consequences of completely disrupting CCR5 expression in human cells in vivo are unknown. Thus, expression of a TRIM5a-based 
Results

A screen based on random mutagenesis of TRIM5a
A human TRIM5a mutant library was constructed by error-prone PCR of the PRYSPRY domain (Figure 1a ), the only region of this protein known to influence retroviral target specificity. The frequency of mutations was within the desired range of 1-2 per clone ( Figure 1b) . The mutations introduced were almost exclusively (97%) substitutions, with a strong bias toward mutations at A/T residues (approximately 80%; see Figure 1c ), as predicted from this type of mutagenesis. As expected, mutations were scattered all along the PRYSPRY domain ( Figure  1d ). Some regions, like the first variable region and the region between v3 and v4, appeared to be mutational hot-spots, and this seems to correlate partly with their high A/T content. Among 94 substitutions analyzed, 34 (36%) were silent and 17 (18%) were present more than once (eight were present twice, and one was present three times). Thus, enrichment for particular point mutations, a recurring problem in PCR-based random mutagenesis, was relatively low in our screen by virtue of the PCR conditions used (high amount of template DNA, low number of cycles). No mutations were found in TRIM5a hu regions upstream of the PRYSPRY domain. The library was retrovirally transduced into human cells rather than in the cell lines of murine or feline origin that are often used to study TRIM5a-mediated restriction. This might seem somewhat counterintuitive at first, considering that human cells express endogenous wildtype TRIM5a, creating the possibility of functional interference between the two proteins. 44 However, considering that the ultimate goal is to inhibit HIV-1 replication in human recipients, we judged that human cells should be used in the screen itself. In addition, published data suggest that overexpressed, exogenous TRIM5a is dominant over endogenous TRIM5a, 44 most probably because of large differences in protein amounts. Untransduced cells were eliminated by puromycin treatment. Functional screening was carried out by infecting the library-expressing cells with large doses (typically leading to 99% infected cells) of an HIV-1 vector expressing green fluorescent protein (GFP) (HIV-1 TRIPÀCMVÀGFP ) then isolating cells that were GFP negative and thus putatively resistant to HIV-1 infection. This approach is the same one that originally led to the discovery of TRIM5a as an antiviral protein by the Sodroski laboratory. 3 In a second step of functional Figure 1e ). In step three, transgenic TRIM5a hu were PCR amplified from all of these clones and were re-introduced into naive TE671 cells by retroviral transduction using the MIP vector again. These cells were also challenged with four doses of HIV-1 TRIP-CMV-GFP , and that time we found that only one cell line (clone 64) showed significant resistance to HIV-1 (Figure 1e ). Therefore, resistance to HIV-1 infection in the other 39 clonal cell lines from the second step of functional screening was due to factors other than the expression of exogenous TRIM5a. Accordingly, sequencing showed that some of these TRIM5a coding sequences did not even carry mutations (not shown). We did not analyze the 39 false positives any further.
Targeted mutagenesis of Arg332 and Arg335 within PRYSPRY first variable region
TRIM5a complementary DNA in clone 64 contained the A1003G mutation, resulting in an arginine to glycine substitution at position 335 of the protein. It also had a silent mutation (A906C). Arg335 is located in the hypervariable region v1 of the PRYSPRY domain and has been positively selected during recent evolution. 33 Humans, chimpanzees and gorillas are the only known primates to have a positively charged residue at this position. 31 Partly for that reason, the role of this residue in the inability of TRIM5a hu to restrict HIV-1 had been suspected before, 45 but data published so far has suggested that it was only a minor determinant of HIV-1 restriction. For instance, TRIM5a rh with an arginine at this position instead of a leucine was still fully able to restrict HIV-1. 35 Li et al. 36 constructed the reciprocate R335L mutation of TRIM5a hu and found that it weakly inhibited HIV-1; in addition, the double-mutant R332P/ R335L restricted HIV-1 less efficiently than R332P alone. Therefore, isolation of an Arg335 mutant in our screen was rather unexpected. We hypothesized that this discrepancy was simply caused by different substitutions (to leucine in Li's paper, to glycine as found in our screen).
A computerized model for the structure of the PRYSPRY domain of TRIM5a hu has been suggested, based on the known crystal structures of similar domains within other proteins. 46 In this model, the variable region v1 forms a loop that protrudes from the rest of the domain and is essentially an insertion compared with other SPRY domains. Owing to its flexibility, the exact spatial conformation of this region is more uncertain than that of the more structured globular core. However, the side chains of Arg332 and Arg335 clearly are solvent exposed and would be likely to come to close contact with the viral capsid ( Figure 2a ). To examine the respective roles of arginines 332 and 335 in the restriction range of TRIM5a hu , we constructed an array of mutations at position 335 and we also constructed double mutations ( Figure 2b) . First, to insure that R335G was the sole Targeted molecular evolution of TRIM5a QT Pham et al mutation in clone 64 causing the observed phenotypical change, we reintroduced the mutation in the parental plasmid. To analyze the possibility that increased restriction of HIV-1 was caused by suppression of the positive charge at position 335, we made the arginine-tolysine mutant R335K, which maintains this positive charge. We also constructed the basic-to-acidic mutations R335D and R335E, replacing the positive charge by a negative one. We also substituted Arg335 into two hydrophobic residues, one aromatic (R335F) and one aliphatic (R335L; Li et al. 36 mutation), and an additional mutant had Arg335 deleted. Arg332 was mutated to glycine, which was one of the mutations at this position conferring a high HIV-1 restriction phenotype. Finally, we combined R332G with R335G or with R335E. These two double mutations have a -2 and -3 net effect on the protein's charge, respectively. All mutated TRIM5a hu were transduced into TE671 cells and into the lymphocytic T-cell line SUP-T1.
Restriction of HIV-1 by wild-type and mutant TRIM5a hu
All the TE671 cell lines created were challenged with retroviral vectors derived from HIV-1 ( Figure 3a and Table 1 ) and from other retroviruses (Supplementary Figure 1 and Table 1 ). All retroviral vectors expressed the enhanced GFP, which thus served as a marker to quantitate the percentages of infected cells. As shown Figure 3a , overexpression of wild-type TRIM5a hu slightly inhibited HIV-1 infection (less than twofold), an effect observed by others before. 13, 35, 47 All mutants caused a significant decrease in permissiveness to HIV-1 ( Figure  3a and Table 1 ). R332G and R335G both restricted HIV-1 by 10-to 20-fold. Clone 64 TRIM5a hu also inhibited HIV-1 to the same extent, confirming that R335G was the only mutation in this clone having a role in the restriction. The least efficient mutant for the restriction of HIV-1 was R335K (sixfold), suggesting that suppression of the positive charge at this position was indeed needed for maximum restriction. R335L and R335F similarly had a weak effect on HIV-1 infection, suggesting that a hydrophobic residue at this position was detrimental for the restriction of HIV-1. All other mutations decreased HIV-1 infection by up to 35-fold, and the mutant with the strongest effect was the double substitution R332G/R335G, showing that the two mutations had partially additive effects.
Expression of exogenous TRIM5a in these cell lines was assessed by western blotting using an antibody recognizing the C-terminal FLAG tag. Among other similarly FLAG-tagged TRIM5a orthologues, the human version has been found difficult to detect in the past. By optimizing the experimental conditions, we were able to detect all TRIM5a hu mutants in TE671 cells and all of them were found to have the expected size (Figure 3b) . Levels of expression seemed to vary substantially between mutants. Differences in efficiencies of 
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Restriction by various TRIM5a orthologues have often been studied in cell lines of cat or mouse origin, which do not express endogenous TRIM5a. To gain insight into the cell context dependency of HIV-1 restriction by TRIM5a hu mutants, we transduced R332G and R332G/ R335G TRIM5a hu in both TE671 and murine Mus dunni tail fibroblast (MDTF) cells (Figure 3c ). As expected, TRIM5a rh decreased HIV-1 replication by 100-fold in both cell lines, while TRIM5a hu had a small inhibitory effect in both cell contexts (although the restriction was stronger in human cells). R332G TRIM5a hu decreased HIV-1 replication by five-to eightfold in both cell lines, consistently with previous results. Interestingly, in MDTF cells R332G/R335G restricted HIV-1 at levels similar to the single mutant R332G. In TE671 cells, R332G/R335G was again significantly more efficient than R332G alone and decreased HIV-1 replication by approximately 20-fold (Figure 3c ). It is not clear whether this observed cell context dependency is due to the presence of low levels of endogenous TRIM5a hu in human cells or to some other cellular factor. However, this observation argues in favor of performing this type of screen directly in human cells, which was the strategy followed here.
Restriction of other retroviruses
As also shown in Supplementary Figure 1 and Table 1 , HIV-2 was significantly inhibited (10-fold) by overexpressed TRIM5a hu , an observation previously reported. 13 We also examined the effect of our constructs on the replication of EIAV and N-MLV, two viruses that are restricted by the human endogenous TRIM5a. EIAV replication was further decreased five times by overexpression of wild-type TRIM5a hu . Several mutations (R332G, R335K, R335) inhibited EIAV at significantly higher levels (up to 12-fold) while the double-mutation R332G/R335G had a smaller effect (threefold). Thus, arginines 332 and 335 are also determinants in the restriction of nonsimian lentiviruses.
The N-MLV and B-tropic MLV (B-MLV) Gag proteins differ by a few amino acids, 49 and amino acid 110 in the capsid domain determines the sensitivity of MLV to TRIM5a hu and to Fv1, another restriction factor functionally (if not structurally) related to TRIM5a. 50, 51 In our hands, N-MLV replication was decreased by overexpression of wild-type TRIM5a hu (Supplementary Figure 1) . This effect was greater at relatively high amounts of viral input (for example, 100 ml of virus) than at lower doses such as 25 ml. This is likely due to the well-known effect of saturation of the restriction at high virus doses: 50, 52 endogenous TRIM5a hu is saturated by large amount of incoming N-MLV capsids but overexpression of TRIM5a hu restores restriction. That both N-MLV and EIAV were significantly inhibited by overexpressed TRIM5a hu suggests that the endogenous protein is expressed at levels too low for optimal restriction, at least in the absence of interferons. 53, 54 Mutations at position 332 and 335 had modest effects on the restriction of N-MLV by TRIM5a hu (Supplementary Figure 1 and Infection with a B-MLV vector was in most cases only marginally affected by mutations at the two arginines, with the exception of R335G and R335K, which inhibited this virus by approximately 5-fold and 20-fold, respectively. All the other mutants behaved like the mocktransduced cells. These data show that Arg335 also influences the sensitivity of N-MLV and B-MLV to the restriction by TRIM5a hu , but in a manner strikingly different from what is observed with lentiviruses: (i) unlike that of lentiviruses, restriction of N-MLV is not significantly affected by the introduction of hydrophobic residues at position 335; (ii) B-MLV is the only virus analyzed here that is specifically inhibited by the R335K mutation. It is noteworthy that another group reported that B-MLV could be restricted by TRIM5a hu bearing a mutation at Tyr336. 55 
Restriction of HIV-1 in a T-cell line
We then analyzed the level of protection conferred by TRIM5a hu mutants in the T-cell line SUP-T1. These cells were transduced with the various TRIM5a hu variants and controls, and untransduced cells were eliminated by puromycin treatment. As shown in Figure 4a , we first challenged these cells with the same HIV-1-derived vector (HIV-1 TRIPÀCMVÀGFP ) that had been used in TE671 cells. TRIM5a rh caused a decrease in permissiveness to HIV-1 of approximately 25-fold, which is significantly smaller than what is typically found in fibroblasts (100-fold or more). This is consistent with results published by others. 56 R332G and R335G both inhibited HIV-1 by approximately eightfold, while R335K had no restrictive effect at all. Overall, mutants showed phenotypes similar to what had been observed in TE671 cells. The two double mutants restricted HIV-1 to nearly TRIM5a rh levels, confirming that mutations at Arg332 and Arg335 had additive effects.
To analyze the protection conferred by TRIM5a hu mutants in more physiological conditions, we challenged the SUP-T1 cell lines with a replication-competent HIV-1 clone derived from NL4-3 but expressing GFP in place of Nef. This virus enters the cells by virtue of its own envelope proteins instead of being pseudotyped with VSV-G. All but one of the viral proteins is encoded and expression of GFP allows the quantification of cells' permissiveness to HIV-1 NLÀGFP by fluorescence-activated cell sorting. In this context, a group of mutants that included R335G, R335L, R335F, R335 and R335D all decreased HIV-1 replication by approximately 10-fold, while R332G had a slightly smaller effect. Again, the two double mutants inhibited HIV-1 the most efficiently (approximately 50-fold) and were nearly as restrictive as TRIM5a rh . Collectively, the data in Figures 3 and 4 show that while the inhibition of HIV-1 by particular TRIM5a hu mutants can vary to some extent depending on cell type Targeted molecular evolution of TRIM5a QT Pham et al and virus used, the R332/R335 double mutants consistently show the best prospects as anti-HIV-1 transgenes.
Restriction over multiple replication cycles
We then analyzed the inhibition of HIV-1 propagation by these double mutants on multiple replication cycles. It has been shown recently that in in vitro T-cell cultures, and probably in most instances in vivo, HIV-1 is transmitted from one cell to the next through virological synapses 57-59 rather than through cell-free viral particles. This mode of transmission may result in different sensitivities of the incoming viruses to TRIM5a. It may also result in TRIM5a targeting susceptible retroviruses not just at post-entry stages but also at later stages of the retroviral life cycle. 60 We thus aimed at analyzing the potency of the R332/R335 double mutants in the context of cell to cell transmissions. 'Classical' virus spreading assays are initiated by adding cell-free virus on a culture of T cells. In these conditions, the first round of entry events is thus mechanistically different from subsequent rounds. To assay virus spread in more consistent conditions, we infected parental SUP-T1 cells with HIV-1 NL4À3 . The next day, these cells were washed and then placed in culture at a ratio of 1:10 with the SUP-T1 cells expressing wild-type or mutant TRIM5a hu or expressing TRIM5a rh (Figure 5a ). Reverse transcriptase activity was measured in the supernatants of the infected cells for 7 weeks after the initiation of the co-cultures (Figure 5b ). Viral replication peaked after 14 days of virus spread in control (mock-transduced) cells. HIV-1 replication in cells expressing exogenous TRIM5a hu was slightly delayed, consistent with the small inhibition effect observed in other experimental settings. Spreading infections in TRIM5a rh -, R332G/R335G and R332G/ R335E TRIM5a hu -expressing cells were all strongly delayed as shown by the absence of reverse transcriptase activity until day 28. In these three cell lines, replication seems to plateau at around day 30, and a second peak is observed at around day 42. The possibility that HIV-1 may have incorporated mutations allowing replication in restrictive conditions is currently being analyzed. The single-mutant R332G was included in this experiment and consistently with the one-cycle assays, we found that it caused a significant replication peak delay (1 week) yet the inhibition was clearly much weaker than with the two double mutants. It is noteworthy that replication of HIV-1 in cells expressing TRIM5a rh and the two double mutants of TRIM5a hu did not induce obvious cytopathic effects, while infection of control cells and of cells transduced with R332G TRIM5a hu resulted in massive loss of cells coinciding with the replication peak.
Expression of transgenic wild-type and mutant TRIM5a hu was assessed by western blotting in SUP-T1 cells. R332G and the two double mutants were expressed at similar levels and at slightly higher levels than the wild-type control. Therefore, and as in the TE671 cells, 
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In this work, we used targeted in vitro molecular evolution to identify and characterize a new mutant of TRIM5a hu (R335G) that shows restriction against HIV-1. Clearly, our results show the usefulness of mutagenic screens in the generation of novel antiviral gene candidates. Arg332 and Arg335 both seem to prevent targeting of HIV-1 by TRIM5a hu through the presence of a positive charge and removal of the charge at position 335 enhances restriction to the same extent as removal of that of Arg332. One important difference is that all mutations at Arg332 (except R332K) increase HIV-1 restriction to the same extent, 36 while we show that mutations at Arg335 can have very different effects on the restriction of not only HIV-1 but of other retroviruses as well. This particular amino acid of the v1 region thus seems to represent an important determinant in the interactions between TRIM5a proteins and the viral capsids they target. Removal of the positive charge at Arg332 increases the capacity of TRIM5a hu to bind to HIV-1 capsid, 36 and the mutations at Arg335 described here are expected to have the same effect, although that remains to be shown. It is noteworthy that Arg332 and Arg335 are part of a highly flexible loop (Figure 2a) . One could speculate that this loop makes contact with a region of HIV-1 CA that itself is positively charged, hence preventing efficient interactions. In addition, substituting arginines to glycines within this loop is expected to increase its flexibility even further, perhaps enhancing the capacity of the PRYSPRY domain to adapt to the capsid target protein. Targeted molecular evolution of TRIM5a QT Pham et al
Interpretation of the infectivity assays shown here is potentially complicated by the fact that TRIM5a hu variants were seemingly expressed at different levels. It is noteworthy that R335L, R335F and R335K seemed less stable than the rest of the mutants. Low stability could explain R335L and R335F generally poor restriction potential. However, R335K efficiently restricted B-MLV while the rest of the mutants had little or no activity against this virus. Similarly, R332G was expressed at levels similar to the two double mutants, although it was a less efficient restriction factor against several lentiviruses. Altogether, the correlation between stability and restriction potential appears to be small and probably not relevant at all. Other investigators have found previously that variations in levels of exogenously expressed TRIM5a (for instance by treatment with the stabilizer sodium butyrate) had little effect on restriction activity. 13, 17 To our knowledge, no study had analyzed the extent of protection provided by mutations at Arg332 in T-cell lines or against a fully replicative strain of HIV-1. Our data show that mutating this arginine alone does not provide adequate resistance against HIV-1 in these settings. In contrast, the R332/R335 double mutations described here seem to confer a level of resistance similar to that of TRIM5a rh , one of the most potent natural HIV-1 restriction factors described so far. Of course, characterization of its protective effect in other T-cell lines, other cell types, and in primary cells will be necessary to fully establish its antiviral potency. Similarly, experiments involving other HIV-1 strains, including non-laboratoryadapted ones, will be needed.
Our mutant TRIM5a hu antiviral approach begs the comparison with hT5Cyp, 56 the recently constructed TRIMCyp-like restriction factor with very high HIV-1 restriction activity. Both types of gene are likely to inhibit HIV-1 through the same effector mechanisms, although that remains to be assessed. Both are predicted to show low immunogenicity when used in vivo. hT5cyp probably has higher potency, 56 certainly not a negligible factor. The single most important determinant for success in vivo, however, is likely to be the emergence (or lack thereof) of HIV-1 variants resistant to the transgenic restriction factor used. In that respect, too, both types of transgene are promising, although for different reasons. One might predict that it would be difficult for HIV-1 to escape being targeted by the cyclophilin A domain of hT5cyp, given that it needs to interact with endogenous cyclophilin A for optimal replication. 61, 62 However, it has been suggested that cyclophilin A-independent strains of HIV-1 are circulating among patients. 63 The advantage of the mutant TRIM5a hu approach, on the other hand, lies in its plasticity: additional TRIM5a hu mutants with anti-HIV-1 activity could be found in different and largerscale mutagenic screens than the one described here, and the search for variants that do not lead to the appearance of resistant HIV-1 strains could be fully integrated in this discovery process.
Materials and methods
Cells and plasmids DNAs
Human rhabdomyosarcoma TE671 cells, MDTF and human embryonic kidney 293T cells were maintained in Dulbecco's modified Eagles's medium supplemented with 10% fetal bovine serum and antibiotics at 37 1C Human T lymphoid SUP-T1 cells were cultured in RPMI 1640 supplemented with 10% fetal bovine serum and antibiotics at 37 1C. All cell culture reagents were from Hyclone (Thermo Scientific, Logan, UT, USA).
pMIP-TRIM5a hu , pMIP-TRIM5a rh and mutants of pMIP-TRIM5a hu all express C-terminal FLAG-tagged versions of complementary DNAs and were gifts from Jeremy Luban.
64 pNL4-3, pNL-GFP, pMD-G, pCIG3N, pCIG3B, pCNCG, pDR8.9, pTRIP CMVÀGFP , pCL-Eco, pROD NefÀGFP , pSIV macÀGFP , pONY3.1 and pONY8.0 have all been extensively described before 44, [65] [66] [67] [68] [69] [70] [71] [72] 
Production of retroviral vectors
To produce replication-competent HIV-1, 293T cells plated at 80% confluency in 10-cm Petri dishes were transfected using polyethylenimine (Polysciences, Warringtown, PA, USA) with 10 mg of pNL4-3 or pNL-GFP. All other retroviral vectors were pseudotyped with VSV G. To produce HIV-1 TRIPÀCMVÀGFP , 293T cells were co-transfected with 10 mg of pTRIP CMVÀGFP , 10 mg of pDR8.9 and 5 mg of pMD-G. To produce MLV vectors expressing GFP, 293T cells were similarly co-transfected with 10 mg of pCNCG, 10 mg of pCIG3 N or B, and 5 mg of pMD-G. HIV-2 RODÀGFP and SIV macÀGFP vectors were produced by co-transfection of 10 mg of pROD NefÀGFP or pSIV macÀGFP respectively, and 5 mg of pMD-G. EIAV GFP were produced by co-transfection of 10 mg of pONY3.1, 10 ug of pONY8.0 and 5 mg of pMD-G. Two days postinfection, the supernatants were collected, clarified by low speed centrifugation and stored in 1 ml aliquots at À80 1C.
Library construction
Random mutations were introduced into the PRYSPRY domain of TRIM5a hu using the Diversify PCR Random Mutagenesis Kit (Clontech, Mountain View, CA, USA).
Predefined experimental buffer conditions were tested to select the desired rate of one to two mutations per 600 bp. Buffer conditions #2 of the kit were used and consisted in an excess of dGTP combined with 160 mM of MnSO 4 . Error-prone PCR was performed using 100 ng of pMIP-TRIM5a hu and the following primers: SPRY fwd , 72 1C, 1 min) . PCR products were cleaned of PCR reaction components by using the QIAGEN (Mississauga, ON, USA) QIAQuick PCR purification kit. Aliquots (7 ml out of 50 ml) of each purified product were then mixed together to serve as templates in a second round of PCR, which used the TRIM5 fwd and TRIM5 rev oligonucleotides. DNA was amplified for 25 cycles (98 1C, 20 s; 56 1C, 20 s; 72 1C, 1 min) using the Phusion enzyme. The resulting PCR fragment was gel-purified (Qiagen QIAQuick kit), Targeted molecular evolution of TRIM5a QT Pham et al digested with Xho1 and EcoR1 and ligated to pMIP cut with the same enzymes. Escherichia coli DH5a were transformed with the ligation products, yielding a library of 24 600 clones. A number of colonies were used to start small liquid cultures to prepare DNA for sequencing of individual clones. The remainder were harvested and mixed together in liquid Luria-Bertani (LB) medium, and an aliquot of this resuspension was used to start a 125-ml overnight culture. Plasmid DNA was purified using the Qiagen Midiprep kit and used to produce MLV-derived retroviral vectors. For this, 10 mg of the library DNA were mixed with 10 mg of pCl-Eco and 5 mg of pMD-G and this mixture was transfected using polyethylenimine in 293T cells plated at 80% confluence in a 10-cm plate. Two days later, the supernatant of this plate was collected, aliquoted and frozen at À80 1C. To express the library in human TE671 cells, cells were plated in six-well plates at 250 000 cells per well and infected in duplicates with various amounts of the mutant-library MLV vectors. Two days later, cells were treated with 2 mg ml -1 of puromycin. This concentration of puromycin is relatively high, allowing most of the nontransduced cells to die in o24 h. The day after puromycin was added, mortality was estimated visually, and we only maintained in culture the cells infected at a virus dose leading to no more than 10% transduced cells. These cells were pooled and cultured in 10-cm plates. For the functional selection, cells at approximately 10% confluence in 10-cm dishes were challenged three consecutive times with a preparation of HIV-1 TRIPÀCMVÀGFP . In all, 5 ml of the undiluted GFP-expressing vector were used per plate and per infection, and infections were allowed to proceed for 16 h each. Approximately a week later, cells were sorted by fluorescence-activated cell sorting and GFP-negative cells (typically 1% of total intact cells) were plated at 1 cell per well in 96-well plates in Dulbecco's modified Eagles's medium-based culture medium supplemented with 10% conditioned medium (0.45 mm-filtered supernatant of confluent TE671 cells). The surviving clones were grown and challenged with HIV-1 TRIPÀCMVÀGFP in 24-well plates as detailed below.
Site-directed mutagenesis
Mutations were introduced by overlap extension PCR. 73 PCRs were carried out using the high-fidelity Phusion enzyme as detailed above. The following primers were used (the modified codons are underlined):
R332G 
Generation of cells stably expressing TRIM5a variants
Retroviral vectors encoding wild-type TRIM5a hu , TRIM5a rh or mutants of TRIM5a hu proteins were created using the pMIP vector. Recombinant viruses were produced by co-transfecting 293T cells in six-well plates with 2 mg of the appropriate pMIP construct, 2 mg of pCL-Eco and 1 mg of pMD-G. Two days later, supernatants were collected, cleared by low-speed centrifugation and used immediately. For TE671 and SUP-T1, 125 000 cells were plated per well in six-well plates and exposed to 2 ml of MIP-TRIM5a retroviral vectors or with the empty parental vector MIP as a control. Two days post-transduction, cells were placed in medium containing 0.5 mg ml -1 of puromycin (EMD Biosciences, Gibbstown, NJ, USA). Selection was allowed to proceed for 1 week, although untransduced control cells were killed in 2-3 days. Expression of the transduced TRIM5a was analyzed by western blotting, using antibodies directed against the FLAG epitope (mouse monoclonal; Sigma-Aldrich, St Louis, MI, USA) and actin (rabbit polyclonal; Santa Cruz, Santa Cruz, CA, USA).
Viral challenges
For single-cycle infections of TE671 and MDTF, 25 000 cells were seeded in 400 ml per well of 24-well plates. Cells were infected the next day with multiple doses of HIV-1 TRIPÀCMVÀGFP , MLV-N GFP , MLV-B GFP , SIV macÀGFP , EIAV GFP or HIV-2 RODÀGFP . Two days post-infection, adherent cells were trypsinized and fixed in 1% formaldehyde-phosphate-buffered saline while SUP-T1 cells were simply treated with formaldehyde. For HIV-1 NLÀGFP infections, SUP-T1 cells were plated at 2 Â 10 5 cells in 400 ml per well of 24-well plates and infected with a single dose (150 ml) of virus. To avoid the initiation of a second cycle of replication, cells were fixed at 36 h. All cells were subjected to fluorescence-activated cell sorting analysis on a FC500 MPL instrument (Beckman Coulter, Mississauga, ON, USA) using MXP/CXP software. On the basis of light scatter profiles, only intact cells were included in the analysis. GFP-positive cells were gated and counted as a percentage of total intact cells.
For spreading assays, 1.5 Â 10 6 parental SUP-T1 cells were seeded in 2 ml of medium per well of six-well plates. Cells were infected with 15 ml of HIV-1 NL4À3 . 20 h post-infection, cells were harvested by centrifugation at 1200 revolutions per minute for 5 min, washed once with culture medium, and resuspended in 1.5 ml of fresh medium. BIn total, 1.0 Â 10 5 of these infected cells were mixed with 1.0 Â 10 6 SUP-T1 cells expressing wild-type or mutant TRIM5a hu in 1 ml of medium per well of 12-well plates. Between two-thirds and three-quarters of each culture were harvested at various time points after 
